969 related articles for article (PubMed ID: 27718153)
41. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
42. Prognostic score models for survival of nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy and chemotherapy.
Zeng L; Guo P; Li JG; Han F; Li Q; Lu Y; Deng XW; Zhang QY; Lu TX
Oncotarget; 2015 Nov; 6(36):39373-83. PubMed ID: 26415223
[TBL] [Abstract][Full Text] [Related]
43. Survival outcomes and toxicity profiles among patients with nonmetastatic nasopharyngeal carcinoma treated with intensity-modulated radiotherapy (IMRT) versus IMRT + carbon-ion radiotherapy: A propensity score-matched analysis.
Li Y; Guan X; Xing X; Hu C
Head Neck; 2024 Jul; 46(7):1766-1776. PubMed ID: 38591178
[TBL] [Abstract][Full Text] [Related]
44. Individualized concurrent chemotherapy by pretreatment plasma Epstein-Barr viral DNA in II-III stage nasopharyngeal carcinoma: A propensity score matching analysis using a large cohort.
Sun XS; Chen WH; Liu SL; Liang YJ; Chen QY; Guo SS; Wen YF; Liu LT; Xie HJ; Tang QN; Li XY; Yan JJ; Mai HQ; Tang LQ
Cancer Med; 2019 Aug; 8(9):4214-4225. PubMed ID: 31210417
[TBL] [Abstract][Full Text] [Related]
45. Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system.
Sun Y; Tang LL; Chen L; Li WF; Mao YP; Liu LZ; Lin AH; Li L; Ma J
BMC Cancer; 2012 Feb; 12():68. PubMed ID: 22336097
[TBL] [Abstract][Full Text] [Related]
46. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
Kang M; Wang F; Liao X; Zhou P; Wang R
Medicine (Baltimore); 2018 Jun; 97(25):e11118. PubMed ID: 29924009
[TBL] [Abstract][Full Text] [Related]
47. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus neoadjuvant chemotherapy plus concurrent chemoradiotherapy for ascending or descending types of nasopharyngeal carcinoma: A retrospective study.
Lin Q; Lu L; Wang X; Lin Y; Chen Y; Chen H; Chen S; Lin S; Zhang Y; Zheng P; Chen X
Am J Otolaryngol; 2022; 43(1):103193. PubMed ID: 34509080
[TBL] [Abstract][Full Text] [Related]
48. Using neoadjuvant chemotherapy and replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma with intracranial invasion to protect critical normal tissue.
Niu X; Chang X; Gao Y; Hu C; Kong L
Radiat Oncol; 2013 Oct; 8():226. PubMed ID: 24083351
[TBL] [Abstract][Full Text] [Related]
49. Hyperfractionation compared to standard fractionation in intensity-modulated radiation therapy for patients with locally advanced recurrent nasopharyngeal carcinoma.
Lee VH; Kwong DL; Leung TW; Ng SC; Lam KO; Tong CC; Sze CK
Eur Arch Otorhinolaryngol; 2017 Feb; 274(2):1067-1078. PubMed ID: 27738820
[TBL] [Abstract][Full Text] [Related]
50. Elevated high-sensitivity C-reactive protein levels predict decreased survival for nasopharyngeal carcinoma patients in the intensity-modulated radiotherapy era.
Tang LQ; Hu DP; Chen QY; Zhang L; Lai XP; He Y; Xu YX; Wen SH; Peng YT; Chen WH; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mai HQ
PLoS One; 2015; 10(4):e0122965. PubMed ID: 25874450
[TBL] [Abstract][Full Text] [Related]
51. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma.
Zhao L; Wan Q; Zhou Y; Deng X; Xie C; Wu S
Radiother Oncol; 2011 Jan; 98(1):23-7. PubMed ID: 21040992
[TBL] [Abstract][Full Text] [Related]
52. Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study.
Su Z; Mao YP; Tang J; Lan XW; OuYang PY; Xie FY
Tumour Biol; 2016 Apr; 37(4):4429-38. PubMed ID: 26499947
[TBL] [Abstract][Full Text] [Related]
53. Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma.
Yi J; Huang X; Gao L; Luo J; Zhang S; Wang K; Qu Y; Xiao J; Xu G
Radiat Oncol; 2014 Feb; 9():56. PubMed ID: 24533569
[TBL] [Abstract][Full Text] [Related]
54. Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy.
Li WF; Li YQ; Chen L; Zhang Y; Guo R; Zhang F; Peng H; Sun Y; Ma J
BMC Cancer; 2015 Oct; 15():810. PubMed ID: 26506820
[TBL] [Abstract][Full Text] [Related]
55. Prognostic Value of Cavernous Sinus Invasion in Patients with Nasopharyngeal Carcinoma Treated with Intensity-Modulated Radiotherapy.
Liao JF; Ma L; Du XJ; Lan M; Guo Y; Zheng L; Xia YF; Luo W
PLoS One; 2016; 11(1):e0146787. PubMed ID: 26824230
[TBL] [Abstract][Full Text] [Related]
56. The impairment of induction chemotherapy for stage II nasopharyngeal carcinoma treated with intensity-modulated radiotherapy with or without concurrent chemotherapy: A propensity score-matched analysis.
Lai Y; Wang C; Yang X; He S; Wang Y; Chen Y
Cancer Med; 2023 Feb; 12(3):2970-2978. PubMed ID: 36114787
[TBL] [Abstract][Full Text] [Related]
57. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
Au KH; Ngan RKC; Ng AWY; Poon DMC; Ng WT; Yuen KT; Lee VHF; Tung SY; Chan ATC; Sze HCK; Cheng ACK; Lee AWM; Kwong DLW; Tam AHP
Oral Oncol; 2018 Feb; 77():16-21. PubMed ID: 29362121
[TBL] [Abstract][Full Text] [Related]
58. A Study of 358 Cases of Locally Advanced Nasopharyngeal Carcinoma Receiving Intensity-Modulated Radiation Therapy: Improving the Seventh Edition of the American Joint Committee on Cancer T-Staging System.
Zhou Q; He Y; Zhao Y; Wang Y; Kuang W; Shen L
Biomed Res Int; 2017; 2017():1419676. PubMed ID: 28265567
[TBL] [Abstract][Full Text] [Related]
59. [Effect of adaptive replanning on adverse reactions and clinical outcome in nasopharyngeal carcinoma treated by helical tomotherapy].
Yao W; DU L; Ma L; Feng L; Cai B; Xu S; Xie C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 May; 38(5):468-75. PubMed ID: 23719523
[TBL] [Abstract][Full Text] [Related]
60. Superiority of intensity-modulated radiation therapy in nasopharyngeal carcinoma with skull-base invasion.
Liao S; Xie Y; Feng Y; Zhou Y; Pan Y; Fan J; Mi J; Qin X; Yao D; Jiang W
J Cancer Res Clin Oncol; 2020 Feb; 146(2):429-439. PubMed ID: 31677113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
